Matches in SemOpenAlex for { <https://semopenalex.org/work/W2242113274> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2242113274 endingPage "8500" @default.
- W2242113274 startingPage "8500" @default.
- W2242113274 abstract "8500 Background: A prior pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in untreated patients with diffuse large B-cell lymphoma demonstrated feasibility and safety. This multicenter phase II study was carried out to assess efficacy. Methods: Patients received chemotherapy on the following schedule: epratuzumab 360 mg/m2, rituximab 375 mg/m2, and standard dose CHOP every 3 weeks for 6 cycles. Weekly blood counts were obtained to monitor hematological toxicity. Primary endpoint was 12 month event free survival (EFS12). Secondary endpoints were complete response rate (CR), overall response rate (ORR). An interim analysis was planned when the first 34 eligible patients are evaluable for EFS12. Results: 107 patients were accrued from Feb 2006 to Aug 2007. 29 patients were ineligible based on CD22 negative (11), inadequate pathology or transformed histology (17), or cancel (1) resulting in 78 evaluable patients. Baseline patient characteristics for the entire patient population included median age 62 (range 21–82); 59 patients were male. Most patients had advanced stage (82%); majority had low or intermediate IPI. 72 (67%) patients had an elevated LDH. Performance sore was 0–1 in 94 pts and 2–3 in 13 pts. Overall, 104 patients are evaluable for toxicity. 71 patients (68%) developed grade 4 neutropenia, grade 3 or 4 anemia (9%) and thrombocytopenia (13%). Non- hematological adverse events included neuro-sensory (45%), fatigue (36%), and vomiting (28%). The most common grade 3 or 4 treatment related event was febrile neutropenia (17%). This study has met full accrual. At the time of the planned interim analysis, response rate for these 34 patients is 16 CR, 3 CRu (56% CR + CRu), 13 PR (38%), and 2 SD with an ORR of 94%. Data on the primary endpoint (EFS12) is still maturing and will be reported at the meeting. Conclusions: ER-CHOP every 21 days is safe. The ORR is encouraging; further analysis will determine if this regimen should be evaluated in a phase III randomized study. No significant financial relationships to disclose." @default.
- W2242113274 created "2016-06-24" @default.
- W2242113274 creator A5004152557 @default.
- W2242113274 creator A5006101210 @default.
- W2242113274 creator A5047509474 @default.
- W2242113274 creator A5048644166 @default.
- W2242113274 creator A5051439028 @default.
- W2242113274 creator A5074099210 @default.
- W2242113274 creator A5081957836 @default.
- W2242113274 date "2008-05-20" @default.
- W2242113274 modified "2023-09-26" @default.
- W2242113274 title "A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma" @default.
- W2242113274 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.8500" @default.
- W2242113274 hasPublicationYear "2008" @default.
- W2242113274 type Work @default.
- W2242113274 sameAs 2242113274 @default.
- W2242113274 citedByCount "5" @default.
- W2242113274 crossrefType "journal-article" @default.
- W2242113274 hasAuthorship W2242113274A5004152557 @default.
- W2242113274 hasAuthorship W2242113274A5006101210 @default.
- W2242113274 hasAuthorship W2242113274A5047509474 @default.
- W2242113274 hasAuthorship W2242113274A5048644166 @default.
- W2242113274 hasAuthorship W2242113274A5051439028 @default.
- W2242113274 hasAuthorship W2242113274A5074099210 @default.
- W2242113274 hasAuthorship W2242113274A5081957836 @default.
- W2242113274 hasConcept C126322002 @default.
- W2242113274 hasConcept C141071460 @default.
- W2242113274 hasConcept C203092338 @default.
- W2242113274 hasConcept C2776694085 @default.
- W2242113274 hasConcept C2776755627 @default.
- W2242113274 hasConcept C2777063308 @default.
- W2242113274 hasConcept C2778559949 @default.
- W2242113274 hasConcept C2778720950 @default.
- W2242113274 hasConcept C2778850193 @default.
- W2242113274 hasConcept C2779338263 @default.
- W2242113274 hasConcept C2779429289 @default.
- W2242113274 hasConcept C2779725641 @default.
- W2242113274 hasConcept C2780653079 @default.
- W2242113274 hasConcept C31760486 @default.
- W2242113274 hasConcept C535046627 @default.
- W2242113274 hasConcept C71924100 @default.
- W2242113274 hasConcept C90924648 @default.
- W2242113274 hasConceptScore W2242113274C126322002 @default.
- W2242113274 hasConceptScore W2242113274C141071460 @default.
- W2242113274 hasConceptScore W2242113274C203092338 @default.
- W2242113274 hasConceptScore W2242113274C2776694085 @default.
- W2242113274 hasConceptScore W2242113274C2776755627 @default.
- W2242113274 hasConceptScore W2242113274C2777063308 @default.
- W2242113274 hasConceptScore W2242113274C2778559949 @default.
- W2242113274 hasConceptScore W2242113274C2778720950 @default.
- W2242113274 hasConceptScore W2242113274C2778850193 @default.
- W2242113274 hasConceptScore W2242113274C2779338263 @default.
- W2242113274 hasConceptScore W2242113274C2779429289 @default.
- W2242113274 hasConceptScore W2242113274C2779725641 @default.
- W2242113274 hasConceptScore W2242113274C2780653079 @default.
- W2242113274 hasConceptScore W2242113274C31760486 @default.
- W2242113274 hasConceptScore W2242113274C535046627 @default.
- W2242113274 hasConceptScore W2242113274C71924100 @default.
- W2242113274 hasConceptScore W2242113274C90924648 @default.
- W2242113274 hasIssue "15_suppl" @default.
- W2242113274 hasLocation W22421132741 @default.
- W2242113274 hasOpenAccess W2242113274 @default.
- W2242113274 hasPrimaryLocation W22421132741 @default.
- W2242113274 hasRelatedWork W1970150235 @default.
- W2242113274 hasRelatedWork W2088541499 @default.
- W2242113274 hasRelatedWork W2110489999 @default.
- W2242113274 hasRelatedWork W2166223128 @default.
- W2242113274 hasRelatedWork W2213920779 @default.
- W2242113274 hasRelatedWork W2242113274 @default.
- W2242113274 hasRelatedWork W2888800187 @default.
- W2242113274 hasRelatedWork W2935716814 @default.
- W2242113274 hasRelatedWork W3026939985 @default.
- W2242113274 hasRelatedWork W4250500771 @default.
- W2242113274 hasVolume "26" @default.
- W2242113274 isParatext "false" @default.
- W2242113274 isRetracted "false" @default.
- W2242113274 magId "2242113274" @default.
- W2242113274 workType "article" @default.